They include liver function abnormalities, memory problems, muscle aches and diabetes.
Inclusion criteria are a SDS-BMI ≥ 3.0 according to the growth curves based on the fourth Dutch National Growth Study of 1997 (this corresponds to the 99.9th percentile) or a SDS-BMI ≥ 2.3 (corresponding to the 99th percentile) with obesity related morbidity (e.g. obstructive sleep apnea syndrome, hyperinsulinemia, diabetes type 2, liver function disorders, dyslipidemia, musculoskeletal problems).
The most frequent AEs were musculoskeletal problems, abnormal liver function tests, nausea, changes in white blood cell counts and vomiting (table 2).
For dual therapy, patients have associated concerns regarding disease progression, loss of liver function and other potential health problems with treatment initiation [ 43, 44].
We excluded patients with any acute or chronic diabetes complications, unstable angina, myocardial infarction or heart failure, chronic gastrointestinal disease or abnormal liver function, renal insufficiency, or clinical problems potentially causing hyperglycemia, including infection, thyroid disease, or surgery.
You may experience gastrointestinal problems or abnormal liver function.
For example, you should not take the ant-craving medication naltrexone if your lab work reveals problems with your liver function.[33].[33]
The nutrition scale was assumed to involve problems caused by impaired liver function, but items regarding weight loss may also have been affected by cancer progression.
In particular, there may have been problems related to impaired liver function and there was a high incidence of thromboembolic events.
